Section 6.1: Obstructive Lung Diseases

Obstructive Lung Diseases: Diagnostic and Therapeutic Paradigms

Obstructive lung diseases are characterized by expiratory airflow limitation, defined spirometrically by a post-bronchodilator forced expiratory volume in one second to forced vital capacity ratio of less than 0.70 (FEV1/FVC < 0.70). The clinical focus for the USMLE Step 3 rests on acute exacerbation management, stepwise maintenance therapy, and interventions that alter survival in asthma and chronic obstructive pulmonary disease (COPD).

Acute Asthma Exacerbation Protocol

An acute asthma exacerbation is a medical emergency. Severity assessment must guide the level of care. Clinical indicators of a severe exacerbation include a respiratory rate greater than 30 breaths/min, accessory muscle use (supraclavicular or intercostal retractions), fragmented speech (inability to speak in full sentences), and a peak expiratory flow (PEF) of less than 50% predicted.

The immediate management protocol includes:

• Inhaled Bronchodilators: Administer high-dose short-acting beta2-agonists (SABA; e.g., albuterol 2.5-5 mg) combined with a short-acting muscarinic antagonist (SAMA; e.g., ipratropium bromide 0.5 mg) via nebulization or metered-dose inhaler (MDI) with spacer every 20 minutes for three doses in the first hour.
• Systemic Corticosteroids: Administer early (within the first hour) to reduce airway inflammation. Oral prednisone (40-60 mg) is preferred and equivalent in efficacy to intravenous (IV) methylprednisolone (60-125 mg). IV administration is reserved for patients who cannot tolerate oral intake, are vomiting, or have impending respiratory failure.
• Supplemental Oxygen: Titrate to maintain an arterial oxygen saturation (SpO2) of 93-95% (94-98% in pregnant patients or those with coronary artery disease).
• Intravenous Magnesium Sulfate: A single dose of IV magnesium sulfate (2 g over 20 minutes) is indicated for patients with severe exacerbations (PEF < 50%) who fail to respond to initial inhaled therapy.

Critical Step 3 testing point: A normal or elevated partial pressure of carbon dioxide (PaCO2 >= 40 mmHg) or a worsening respiratory acidosis (pH < 7.35) in a tachypneic patient is an alarm sign. Hyperventilating patients should be hypocapnic (PaCO2 < 35 mmHg); a normalizing PaCO2 indicates respiratory muscle fatigue and diaphragmatic failure, necessitating immediate endotracheal intubation and mechanical ventilation. Noninvasive positive pressure ventilation (NIPPV) is generally avoided in severe asthma due to the risk of rapid deterioration.

Step-Wise Chronic Asthma Management

Chronic asthma management aims to prevent exacerbations and achieve symptom control. Modern guidelines discourage SABA monotherapy due to increased mortality risks; inhaled corticosteroids (ICS) are the cornerstone of therapy.

• Steps 1 & 2 (Intermittent to Mild Persistent): The preferred approach is as-needed low-dose ICS-formoterol (Single Maintenance and Reliever Therapy, or SMART). Formoterol's rapid onset allows it to act as both a quick-relief bronchodilator and an anti-inflammatory controller. Alternatively, daily low-dose ICS plus as-needed SABA is acceptable.
• Step 3 (Moderate Persistent): Daily low-dose ICS-formoterol maintenance and reliever therapy, or daily low-dose ICS-LABA (e.g., fluticasone-salmeterol) with as-needed SABA.
• Step 4 (Moderate to Severe Persistent): Daily medium-dose ICS-formoterol (SMART) or daily medium-dose ICS-LABA with as-needed SABA.
• Step 5 (Severe Persistent): Daily high-dose ICS-LABA plus a LAMA (e.g., tiotropium). Patients with refractory symptoms require phenotypic evaluation for biologic therapies: omalizumab for IgE-mediated allergic asthma; mepolizumab or benralizumab for eosinophilic asthma; and dupilumab (anti-IL-4Ra) for moderate-to-severe eosinophilic or oral steroid-dependent asthma.

Counsel patients on proper MDI spacer use and the necessity of rinsing the mouth and spitting after ICS use to prevent oral candidiasis and dysphonia.

Acute COPD Exacerbation Management

An acute COPD exacerbation is defined by an acute increase in dyspnea, cough, or sputum volume/purulence. Triggered primarily by viral infections (rhinovirus) or bacterial pathogens (H. influenzae, S. pneumoniae, M. catarrhalis), management requires immediate intervention:

• Oxygen Therapy: Titrate oxygen to a target SpO2 of 88-92%. Avoid over-oxygenation, which can precipitate hypercapnia via three mechanisms:
  1. Ventilation-Perfusion (V/Q) Mismatch: Reversal of hypoxic pulmonary vasoconstriction in poorly ventilated alveoli, increasing physiological dead space.
  2. The Haldane Effect: Oxygenation of hemoglobin reduces its affinity for carbon dioxide, displacing CO2 into the blood.
  3. Loss of Hypoxic Drive: A minor decrease in minute ventilation in chronic CO2 retainers.
• Bronchodilators: Nebulized albuterol (SABA) and ipratropium (SAMA) every 1-2 hours.
• Corticosteroids: Oral prednisone (40 mg daily for 5 days) is non-inferior to IV therapy, improves lung function, and reduces hospital stay.
• Antibiotics: Indicated for patients with all three cardinal symptoms (dyspnea, sputum volume, and sputum purulence), or two cardinal symptoms if purulence is one, or any patient requiring mechanical ventilation. Empiric options include azithromycin, doxycycline, or ceftriaxone. Cover Pseudomonas (e.g., with levofloxacin or cefepime) if risk factors are present (FEV1 < 30%, frequent exacerbations, or recent hospitalizations).
• NIPPV/BiPAP: Highly effective for acute respiratory acidosis (pH < 7.35, PaCO2 > 45 mmHg) or severe dyspnea. It decreases intubation rates, hospital stay, and mortality.
• Intubation: Indicated for NIPPV failure, altered mental status, or hemodynamic instability.

Long-Term COPD Therapy

COPD is diagnosed by a post-bronchodilator FEV1/FVC < 0.70. Maintenance therapy is guided by the GOLD classification, which groups patients based on symptoms (mMRC or CAT scores) and exacerbation history:

• Group A (Low symptoms, 0-1 moderate exacerbations): Single bronchodilator (SABA, LABA, or LAMA).
• Group B (High symptoms, 0-1 moderate exacerbations): Long-acting beta2-agonist plus long-acting muscarinic antagonist (LABA + LAMA, e.g., vilanterol-umeclidinium).
• Group E (>= 2 moderate exacerbations or >= 1 hospitalization): LABA + LAMA combination. Add an ICS (triple therapy) only if the blood eosinophil count is >= 300 cells/uL. ICS monotherapy is contraindicated.

Survival-altering interventions in COPD include:

1. Smoking Cessation: The most effective method to slow the FEV1 decline.
2. Long-Term Oxygen Therapy (LTOT): Indicated if resting PaO2 <= 55 mmHg or SaO2 <= 88% (or PaO2 56-59 mmHg / SaO2 89% with cor pulmonale, polycythemia [Hct > 55%], or heart failure). Oxygen must be used >= 15 hours/day to improve mortality.
3. Vaccinations: Annual influenza, pneumococcal (PCV20 or PCV15 followed by PPSV23), COVID-19, and RSV vaccines.